BMO Capital lowered the firm’s price target on Q32 Bio (QTTB) to $22 from $64 but keeps an Outperform rating on the shares. The company reported results from its Phase 2 studies evaluating bempikibart in alopecia areata and atopic dermatitis, and while the results were disappointing, BMO is “not overly surprised” as it leaned cautious on the outcome given the mixed clinical history of bempikibart, the analyst tells investors in a research note. Q32 management still remains positive on the potential for bempikibart, but the firm views the company’s ADX-097’s potential in complement-driven disease as the “more compelling part of the story”, BMO added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio downgraded to Neutral at Guggenheim after failure in atopic dermatitis
- Q32 Bio downgraded to Neutral from Buy at Guggenheim
- Q32 Bio price target lowered to $20 from $80 at Oppenheimer
- Q32 Bio Announces Mixed Results in Clinical Trials
- Q32 Bio price target lowered to $20 from $85 at Piper Sandler